Abstract：
UNASSIGNED: Long-acting injectable buprenorphine (LAIB) has demonstrated a good profile for opioid use disorder (OUD) management. However, there is scarce information on LAIB in OUD patients with comorbid mental disorders (dual disorder patients).
UNASSIGNED: We present a case report on OUD patients with a comorbid mental disorder who have received LAIB for at least 3 months.
UNASSIGNED: Two women and one man with OUD and another comorbid mental disorder were prescribed with LAIB ranging from three to twelve months. Good adherence and opioid abstinence were observed during the follow-up. Psychopathological issues related to comorbid mental disorders were stabilized. A deep discussion on LAIB in this profile of patients is conducted.
UNASSIGNED: LAIB in OUD patients with comorbid mental disorders may be a safe and well tolerated option, similar to OUD patients without comorbid mental disorders. LAIB\'s impact on psychopathological issues requires further high-quality research to understand the real impact of LAIB on OUD and comorbid mental disorders.
UNASSIGNED: We present a case report on OUD patients with a comorbid mental disorder who have received LAIB for at least 3 months.
UNASSIGNED: Two women and one man with OUD and another comorbid mental disorder were prescribed with LAIB ranging from three to twelve months. Good adherence and opioid abstinence were observed during the follow-up. Psychopathological issues related to comorbid mental disorders were stabilized. A deep discussion on LAIB in this profile of patients is conducted.
UNASSIGNED: LAIB in OUD patients with comorbid mental disorders may be a safe and well tolerated option, similar to OUD patients without comorbid mental disorders. LAIB\'s impact on psychopathological issues requires further high-quality research to understand the real impact of LAIB on OUD and comorbid mental disorders.
摘要：
■长效注射用丁丙诺啡（LAIB）已证明对阿片类药物使用障碍（OUD）的管理具有良好的作用。然而,在合并精神障碍的OUD患者(双重障碍患者)中,缺乏有关LAIB的信息.
■我们提供了一份关于患有共病精神障碍且接受LAIB治疗至少3个月的OUD患者的病例报告。
■两名女性和一名男性患有OUD和另一种合并症的精神障碍，在3至12个月的范围内服用LAIB。随访期间观察到良好的依从性和阿片类药物戒断。与合并症精神障碍相关的精神病理学问题得到了稳定。对LAIB在这种患者概况中进行了深入的讨论。
■LAIB在患有精神疾病的OUD患者中可能是一种安全且耐受性良好的选择，与没有共病精神障碍的OUD患者相似。LAIB对精神病理学问题的影响需要进一步的高质量研究，以了解LAIB对OUD和合并症精神障碍的真正影响。
■我们提供了一份关于患有共病精神障碍且接受LAIB治疗至少3个月的OUD患者的病例报告。
■两名女性和一名男性患有OUD和另一种合并症的精神障碍，在3至12个月的范围内服用LAIB。随访期间观察到良好的依从性和阿片类药物戒断。与合并症精神障碍相关的精神病理学问题得到了稳定。对LAIB在这种患者概况中进行了深入的讨论。
■LAIB在患有精神疾病的OUD患者中可能是一种安全且耐受性良好的选择，与没有共病精神障碍的OUD患者相似。LAIB对精神病理学问题的影响需要进一步的高质量研究，以了解LAIB对OUD和合并症精神障碍的真正影响。
